SCHEMBL2832018

SCHEMBL2832018

Cc1c(C(=O)O)c2cccc(F)c2c(=O)n1N

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
MEN1 O00255 2/20 0.39
CES2 O00748 1/20 0.37
CES1 P23141 1/20 0.37
KDM4E B2RXH2 2/20 0.35
PDE10A Q9Y233 1/20 0.35
NOTUM Q6P988 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
ACHE P22303 1/20 0.34
ATM Q13315 2/20 0.34
FEN1 P39748 2/20 0.33
KAT2B Q92831 1/20 0.33
PTGS2 P35354 1/20 0.33
EGFR P00533 1/20 0.33
POLB P06746 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2830105 0.84 ATM (0.43) KMT2AMEN1CES2CES1KDM4E
SCHEMBL2831852 0.83 CNR1 (0.36) KMT2AMEN1KDM4EPDE10AATM
SCHEMBL2837533 0.83 RORC (0.39) KMT2AMEN1KDM4EPDE10ANOTUM
SCHEMBL2834258 0.81 KDM4E (0.43) KMT2AMEN1CES2CES1KDM4E
SCHEMBL2675354 0.81 NOTUM (0.48) KMT2AMEN1KDM4EPDE10ANOTUM
SCHEMBL2149368 0.81 KMT2A (0.43) KMT2AMEN1CES2CES1PDE10A
SCHEMBL2677224 0.81 GAA (0.48) KMT2AMEN1KDM4EPDE10ANOTUM
SCHEMBL1550382 0.80 KMT2A (0.39) KMT2AMEN1CES2CES1PDE10A
SCHEMBL2676694 0.79 NOTUM (0.44) KMT2AMEN1KDM4EPDE10ANOTUM
SCHEMBL4283407 0.79 KMT2A (0.41) KMT2AMEN1CES2CES1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2342182-B1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS LUNDBECK & CO AS H (DK) 2012-11-14 EP disclosed
US-8242134-B2 Isoquinolinone derivatives as NK3 antagonists H. LUNDBECK A/S (DK) 2012-08-14 US disclosed
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-25 US disclosed
WO-2010028655-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS H. LUNDBECK A/S (DK) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100076016-A1 ISOQUINOLINONE DERIVATIVES AS NK3 ANTAGONISTS KCNQ3, KCNK3, GRIK3 KMT2A 891/4885MEN1 2461/4885CES2 3094/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.